Research
Hormonal
GIP(1-30)NH2 results in similar glucagonotropic and insulinotropic effects as GIP(1-42).
GIP(1-30)NH2 could be used similarly to GIP(1-42) in clinical settings for managing insulin and glucagon levels.
StrongSupportsmedium confidence
Compared to placebo, GIP(1-30)NH2 resulted in similar glucagonotropic, insulinotropic, and carboxy-terminal type 1 collagen crosslinks-suppressing effects as GIP(1-42).
Why this rating
Based on the randomized controlled trial design involving healthy men.
Source
The naturally occurring GIP(1-30)NH2 is a GIP receptor agonist in humans
Liva S. L. Krogh et al. · European Journal of Endocrinology · 2023
DOI 10.1093/ejendo/lvac015
other · n=9Cited 8×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →